Informações de Leap Therapeutics Inc

Mais detalhes de Leap Therapeutics Inc Empresa

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.



Código da empresaLPTX

Nome da EmpresaLeap Therapeutics Inc

Data de listagemJan 24, 2017

CEOMr. Douglas E. (Doug) Onsi

Número de funcionários52

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 24

Endereço47 Thorndike St, Suite B1-1

CidadeCAMBRIDGE

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal02141

Telefone16177140360

Sitehttps://www.leaptx.com/

Código da empresaLPTX

Data de listagemJan 24, 2017

CEOMr. Douglas E. (Doug) Onsi

Executivos da empresa Leap Therapeutics Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Douglas E. (Doug) Onsi

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director

140.87K

+30.09%

Dr. Christopher K. Mirabelli, Ph.D.

Chairman of the Board

23.05K

--

Ms. Christine Granfield

Vice President, Head - Regulatory Affairs and Quality

15.90K

--

Dr. Jason Baum, Ph.D.

Chief Scientific Officer

15.90K

--

Dr. James H. Cavanaugh, Ph.D.

Independent Director

214.00

--

Dr. Richard L. Schilsky, M.D.

Independent Director

--

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Director

--

Dr. William W. Li, M.D.

Independent Director

--

Mr. Christian M. Richard

Independent Director

--

Ms. Patricia (Patty) Martin

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Douglas E. (Doug) Onsi

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director

140.87K

+30.09%

Dr. Christopher K. Mirabelli, Ph.D.

Chairman of the Board

23.05K

--

Ms. Christine Granfield

Vice President, Head - Regulatory Affairs and Quality

15.90K

--

Dr. Jason Baum, Ph.D.

Chief Scientific Officer

15.90K

--

Dr. James H. Cavanaugh, Ph.D.

Independent Director

214.00

--

Dr. Richard L. Schilsky, M.D.

Independent Director

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: sáb, 18 de out

Investidores

Tipos de investidores

Investidores

Proporção

Winklevoss Capital Management, LLC

14.62%

Gilead Sciences Inc

9.39%

683 Capital Management LLC

2.55%

Acadian Asset Management LLC

2.18%

Beigene Ltd

2.15%

Outro

69.11%

Investidores

Proporção

Winklevoss Capital Management, LLC

14.62%

Gilead Sciences Inc

9.39%

683 Capital Management LLC

2.55%

Acadian Asset Management LLC

2.18%

Beigene Ltd

2.15%

Outro

69.11%

Tipos de investidores

Investidores

Proporção

Family Office

14.62%

Corporation

11.53%

Investment Advisor

8.64%

Investment Advisor/Hedge Fund

3.10%

Hedge Fund

2.85%

Venture Capital

1.26%

Individual Investor

0.42%

Research Firm

0.11%

Bank and Trust

0.01%

Outro

57.44%

Participação acionária institucional



Atualizado em: dom, 5 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

109

9.05M

16.44%

-10.74M

2025Q2

120

18.70M

45.12%

-8.55M

2025Q1

140

18.85M

45.62%

-6.95M

2024Q4

134

21.35M

55.72%

-2.16M

2024Q3

140

20.83M

54.42%

+2.16M

2024Q2

141

20.87M

54.74%

+4.28M

2024Q1

149

9.36M

39.74%

-1.79M

2023Q4

154

7.72M

34.00%

-3.79M

2023Q3

169

9.36M

44.45%

-1.96M

2023Q2

173

10.09M

52.77%

+1.83M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Gilead Sciences Inc

5.32M

12.84%

--

Jun 30, 2025

683 Capital Management LLC

1.44M

3.48%

-5.76K

-0.40%

Jun 30, 2025

Acadian Asset Management LLC

1.24M

2.99%

-43.42K

-3.39%

Jun 30, 2025

Beigene Ltd

1.22M

2.93%

+1.22M

--

Oct 31, 2024

The Vanguard Group, Inc.

1.16M

2.8%

-14.92K

-1.27%

Jun 30, 2025

Hightower Advisors, LLC

1.10M

2.65%

+1.05M

+2071.98%

Jun 30, 2025

Monaco asset management S.A.M.

1.05M

2.53%

--

Jun 30, 2025

Simplify Asset Management Inc

857.36K

2.07%

-93.61K

-9.84%

Jun 30, 2025

HealthCare Ventures LLC

697.23K

1.68%

+20.91K

+3.09%

Apr 21, 2025

Ver Mais

ETFs Relacionados



Atualizado em: dom, 2 de nov

Nome

Proporção

Simplify Health Care ETF

0.35%

iShares Micro-Cap ETF

0%

Dimensional US Core Equity 1 ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

Avantis US Small Cap Equity ETF

0%

Simplify Health Care ETF

Proporção0.35%

iShares Micro-Cap ETF

Proporção0%

Dimensional US Core Equity 1 ETF

Proporção0%

DFA Dimensional US Sustainability Core 1 ETF

Proporção0%

Avantis US Small Cap Equity ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Data

Tipo

Proporção

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1